Skip to content

Finished goods at other companies

PTH
Pelthos Therapeutics Inc.PTHS
Viatris logo
ViatrisVTRS
West Pharmaceutical Services logo
West Pharmaceutical ServicesWST

Other financials

Income statement

See full
Revenue$9.1M-22.0%
Gross profit$7.2M-30.0%
Operating income-$3.1M-342%
Net income-$3.3M-362%
EPS (diluted)-$0.22-375%

Balance sheet

See full
Cash & equivalents$11.0M-27.1%
Total debt$4.8M-7.1%
Total equity$21.6M-24.5%
Total assets$71.0M+1.5%

Cash flow

See full
Operating cash flow$387.0K-90.1%
CapEx--100%
Free cash flow$387.0K-89.9%

Valuation

See full
Market cap$97.09M+138%
Enterprise value$90.91M+207%
P/S2.3×+1.3×

Profitability

See full
Gross margin82.9%-1.4pp
Operating margin-17.2%-125pp
Net margin-17.6%-103pp
FCF margin3.3%

Returns & leverage

See full
Return on equity-29.4%-86.3pp
Debt / equity0.2×0.0×
Current ratio-0.3×

Where this comes from

Reported directly by Cumberland Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:InventoryFinishedGoodsNetOfReserves.

The official record: Cumberland Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cumberland Pharmaceuticals's finished goods.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cumberland Pharmaceuticals's finished goods?
Cumberland Pharmaceuticals (CPIX) reported finished goods of $5.27M in Q1 2026.
How has Cumberland Pharmaceuticals's finished goods changed year-over-year?
Cumberland Pharmaceuticals's finished goods increased by 75.1% year-over-year, from $3.01M to $5.27M.
What is the long-term trend for Cumberland Pharmaceuticals's finished goods?
Over 5 years (2020 to 2025), Cumberland Pharmaceuticals's finished goods has grown at a -1.0% compound annual growth rate (CAGR), from $5.94M to $5.65M.